Equities

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc

Actions
  • Price (CHF)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments355858
Total Receivables, Net0.750.3051
Total Inventory------
Prepaid expenses2.201.832.35
Other current assets, total------
Total current assets3860112
Property, plant & equipment, net4.775.674.87
Goodwill, net111111
Intangibles, net474747
Long term investments------
Note receivable - long term------
Other long term assets0.030.050.10
Total assets101124175
LIABILITIES
Accounts payable2.052.393.54
Accrued expenses5.057.1325
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.050.040.03
Other current liabilities, total119.4218
Total current liabilities181947
Total long term debt0.090.080.03
Total debt0.140.120.06
Deferred income tax0.272.082.08
Minority interest(1.4)(1.4)(1.32)
Other liabilities, total213134
Total liabilities385082
SHAREHOLDERS EQUITY
Common stock451440435
Additional paid-in capital------
Retained earnings (accumulated deficit)(385)(363)(337)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.07)(3.57)(5.21)
Total equity637392
Total liabilities & shareholders' equity101124175
Total common shares outstanding175170169
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.